DrugPatentWatch Database Preview
Guanfacine hydrochloride - Generic Drug Details
What are the generic drug sources for guanfacine hydrochloride and what is the scope of guanfacine hydrochloride patent protection?
Guanfacine hydrochloride
is the generic ingredient in three branded drugs marketed by Actavis Elizabeth, Apotex Inc, Impax Labs Inc, Mylan Pharms Inc, Sandoz Inc, Sun Pharm Inds Ltd, Teva Pharms Usa, Twi Pharms, Shire, Amneal Pharm, Epic Pharma Llc, Mylan, Watson Labs, and Promius Pharma, and is included in fifteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for guanfacine hydrochloride. Twenty-three suppliers are listed for this compound.
Summary for guanfacine hydrochloride
| US Patents: | 2 |
| Tradenames: | 3 |
| Applicants: | 14 |
| NDAs: | 15 |
| Drug Master File Entries: | 7 |
| Suppliers / Packagers: | 23 |
| Bulk Api Vendors: | 65 |
| Clinical Trials: | 56 |
| Patent Applications: | 845 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for guanfacine hydrochloride |
| DailyMed Link: | guanfacine hydrochloride at DailyMed |
Pharmacology for guanfacine hydrochloride
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
Medical Subject Heading (MeSH) Categories for guanfacine hydrochloride
Synonyms for guanfacine hydrochloride
| [(2,6-Dichlorophenyl)acetyl]guanidine Hydrochloride |
| 29110-47-2 (Parent) |
| 29110-48-3 |
| 29520-14-7 |
| A826918 |
| AB0011596 |
| AC1L2G3E |
| AC1Q3P39 |
| AK105076 |
| AKOS015966858 |
| AKOS030242245 |
| ANW-70740 |
| API0006740 |
| AS-12253 |
| AX8239284 |
| BC202678 |
| Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1) |
| Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride |
| BG0397 |
| BS 100-141 |
| BS-100-141 |
| C9H10Cl3N3O |
| C9H9Cl2N3O.HCl |
| CAS-29520-14-7 |
| CCG-213439 |
| CCG-220339 |
| CHEBI:5559 |
| CHEMBL1200494 |
| Connexyn |
| CS-1254 |
| CTK8C3871 |
| CTK8G0106 |
| D00606 |
| D0WD8M |
| DSSTox_CID_25157 |
| DSSTox_GSID_45157 |
| DSSTox_RID_80708 |
| DTXSID2045157 |
| EINECS 249-443-3 |
| Estulic |
| EU-0100519 |
| FT-0630546 |
| FT-0698181 |
| G 1043 |
| G0414 |
| Guanfacin |
| Guanfacin hydrochloride |
| Guanfacine (hydrochloride) |
| GUANFACINE HCL |
| Guanfacine hydrochloride (JAN/USP) |
| Guanfacine hydrochloride [USAN:JAN] |
| Guanfacine hydrochloride [USAN:USP:JAN] |
| Guanfacine hydrochloride, >=98% (HPLC) |
| Guanfacine hydrochloride, pharmaceutical secondary standard; traceable to USP |
| Guanfacine hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| GUANFACINEHCL |
| GuanfacineHydrochloride |
| Guanfascine Hydrochloride |
| Guarfacine Hydrochloride |
| HMS1569C19 |
| HY-17416 |
| Intuniv |
| J-017395 |
| KB-258655 |
| KS-000017QB |
| LON 798 |
| LP00519 |
| LS-28474 |
| MFCD00798230 |
| MLS000069745 |
| MLS001077329 |
| MLS002222252 |
| MolPort-003-666-686 |
| MolPort-019-997-499 |
| N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide |
| N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride |
| N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride |
| N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride |
| N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride |
| N-[bis(azanyl)methylidene]-2-[2,6-bis(chloranyl)phenyl]ethanamide hydrochloride |
| N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride |
| N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride |
| N-Carbamimidoyl-2-(2,6-dichlorophenyl)acetamide hydrochloride |
| n-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid |
| NCGC00015469-05 |
| NCGC00015469-09 |
| NCGC00093914-01 |
| NCGC00093914-02 |
| NCGC00180965-01 |
| NCGC00261204-01 |
| NSC-759121 |
| NSC759121 |
| Opera_ID_1928 |
| Pharmakon1600-01505435 |
| PML56A160O |
| Prestwick_740 |
| S-877503 |
| s4693 |
| SCHEMBL15603414 |
| SCHEMBL41681 |
| SMR000058453 |
| SPD 503 |
| SPD-503 |
| SPD503 |
| SR-01000075893 |
| SR-01000075893-1 |
| TC-159485 |
| Tenex |
| Tenex (TN) |
| Tox21_110159 |
| Tox21_110159_1 |
| Tox21_500519 |
| UNII-PML56A160O |
| W-5123 |
US Patents and Regulatory Information for guanfacine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax Labs Inc | GUANFACINE HYDROCHLORIDE | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202238-001 | Oct 20, 2015 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Shire | INTUNIV | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022037-003 | Sep 2, 2009 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Impax Labs Inc | GUANFACINE HYDROCHLORIDE | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202238-003 | Oct 20, 2015 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for guanfacine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Promius Pharma | TENEX | guanfacine hydrochloride | TABLET;ORAL | 019032-003 | Nov 7, 1988 | ➤ Sign Up | ➤ Sign Up |
| Shire | INTUNIV | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022037-001 | Sep 2, 2009 | ➤ Sign Up | ➤ Sign Up |
| Promius Pharma | TENEX | guanfacine hydrochloride | TABLET;ORAL | 019032-001 | Oct 27, 1986 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for guanfacine hydrochloride
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: